Clinical Trial Update: Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pyrotinib in combination with trastuzumab and AI for first-line treatment of HER2-positive, hormone receptor-positive metastatic brea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• AI (aromatase inhibitor)
• Pyrotinib (pyrotinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Breast Cancer Female, HER2-positive Breast Cancer | Phase 2 | Status: UNKNOWN